ATDC/TRIM29 drives invasive bladder cancer formation through miRNA-mediated and epigenetic mechanisms

Phillip L. Palmbos, Lidong Wang, Huibin Yang, Yin Wang, Jacob Leflein, McKenzie L. Ahmet, John E. Wilkinson, Chandan Kumar-Sinha, Gina M. Ney, Scott A. Tomlins, Stephanie Daignault, Lakshmi P. Kunju, Xue Ru Wu, Yair Lotan, Monica Liebert, Mats E. Ljungman, Diane M. Simeone

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Bladder cancer is a common and deadly malignancy but its treatment has advanced little due to poor understanding of the factors and pathways that promote disease. ATDC/TRIM29 is a highly expressed gene in several lethal tumor types, including bladder tumors, but its role as a pathogenic driver has not been established. Here we show that overexpression of ATDC in vivo is sufficient to drive both noninvasive and invasive bladder carcinoma development in transgenic mice. ATDC-driven bladder tumors were indistinguishable from human bladder cancers, which displayed similar gene expression signatures. Clinically, ATDC was highly expressed in bladder tumors in a manner associated with invasive growth behaviors. Mechanistically, ATDC exerted its oncogenic effects by suppressing miR- 29 and subsequent upregulation of DNMT3A, leading to DNA methylation and silencing of the tumor suppressor PTEN. Taken together, our findings established a role for ATDC as a robust pathogenic driver of bladder cancer development, identified downstream effector pathways, and implicated ATDC as a candidate biomarker and therapeutic target.

Original languageEnglish (US)
Pages (from-to)5155-5166
Number of pages12
JournalCancer research
Issue number23
StatePublished - Dec 1 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'ATDC/TRIM29 drives invasive bladder cancer formation through miRNA-mediated and epigenetic mechanisms'. Together they form a unique fingerprint.

Cite this